Table 2.
Age categories (yr) | <50 | 50–59 | 60–69 | 70–79 | ≥80 |
---|---|---|---|---|---|
Overall population | |||||
Any FG | |||||
Patients, n | 7856 | 9615 | 10 762 | 7096 | 1789 |
CSM (%) | 61 (0.8) | 159 (1.7) | 242 (2.2) | 261 (3.7) | 112 (6.3) |
OCM (%) | 268 (3.4) | 509 (5.3) | 808 (7.5) | 938 (13.2) | 354 (19.8) |
OM (%) | 329 (4.2) | 668 (6.9) | 1050 (9.8) | 1 199(16.9) | 466 (26.0) |
FG 1–2 | |||||
Patients, n | 6 513 | 7 693 | 8 469 | 5 552 | 1377 |
CMS (%) | 46 (0.7) | 110 (1.4) | 175 (2.1) | 195 (3.5) | 85 (6.2) |
OCM (%) | 213 (3.3) | 412 (5.4) | 658 (7.8) | 764 (13.8) | 275 (20.0) |
OM (%) | 259 (4.0) | 522 (6.8) | 833 (9.8) | 959 (17.3) | 360 (26.1) |
FG 3–4 | |||||
Patients, n | 1 346 | 1 922 | 2293 | 1 544 | 412 |
CSM (%) | 15 (1.1) | 49 (2.5) | 67 (2.9) | 66 (4.3) | 27 (6.6) |
OCM (%) | 55 (4.1) | 97 (5.0) | 150 (6.5) | 174 (11.3) | 79 (19.2) |
OM (%) | 70 (5.2) | 146 (7.6) | 217 (9.5) | 240 (15.5) | 106 (25.7) |
ccRCC cohorts | |||||
Any FG | |||||
Patients, n | 6 652 | 7 812 | 8587 | 5 730 | 1439 |
CSM (%) | 57 (0.9) | 132 (1.7) | 204 (2.4) | 216 (3.8) | 95 (6.6) |
OCM (%) | 221 (3.3) | 419 (5.4) | 681 (7.9) | 802 (14.0) | 308 (21.4) |
OM (%) | 278 (4.2) | 551 (7.1) | 885 (10.3) | 1018 (17.8) | 403 (28.0) |
FG 1–2 | |||||
Patients, n | 5 228 | 6 264 | 6887 | 4 573 | 1115 |
CSM (%) | 44 (0.8) | 112 (1.8) | 165 (2.4) | 174 (3.8) | 70 (6.3) |
OCM (%) | 181 (3.5) | 337 (5.4) | 570 (8.3) | 634 (13.9) | 241 (21.6) |
OM (%) | 225 (4.3) | 449 (7.2) | 735 (10.7) | 808 (17.7) | 311 (27.9) |
FG 3–4 | |||||
Patients, n | 1 424 | 1 548 | 1700 | 1 157 | 324 |
CSM (%) | 13 (0.9) | 20 (1.3) | 39 (2.3) | 42 (3.6) | 25 (7.7) |
OCM (%) | 40 (2.8) | 82 (5.3) | 111 (6.5) | 168 (14.5) | 67 (20.7) |
OM (%) | 53 (3.7) | 102 (6.6) | 150 (8.8) | 210 (18.2) | 92 (28.4) |
ccRCC: clear-cell renal cell carcinoma; CSM: cancer-specific mortality; FG: Fuhrman grade; OCM: other-cause mortality; OM: overall mortality.